Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-002: adjuvant V940 + pembrolizumab versus placebo + pembrolizumab in resected NSCLC
2023-504923-20-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing V940 + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoint: Disease-Free Survival. Planned start Apr 2024; status: authorised.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504923-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504923-20-00.